Galena's Neu Vax vaccine doesn't compete with Herceptin, it targets the additional 50% of patients that are HDER2 positive. The vaccine attacks new cancer cells eliciting an immune response to HER2 protein on cancer surface.

pubblicato il: 16/03/2012 - 04:46